Powered by

TRIANNI Signs Collaboration Agreement with Fred Hutchinson Cancer Research Center for use of The Trianni Mouse Platform

Trianni, Inc. ("TRIANNI") announced today that it has finalized a non-­exclusive license agreement with Fred Hutchinson Cancer Research Center (Fred Hutch), a world leader in lifesaving research to prevent, detect and treat cancer, HIV/AIDS and other deadly diseases, allowing access to The Trianni Mouse, a best-­in-­class monoclonal antibody discovery platform.

"We are pleased to have Fred Hutch as a partner,"stated Dr. David Meininger, Trianni's Chief Business Officer."With the Trianni

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox